Hepatitis A antigen
AssigneeMerck & Co., Inc.
InventorsPhilip J. Provost, Oswald L. Ittensohn, Maurice R. Hilleman
Life of this patent
Estimating the term…
Abstract
Hepatitis A antigen obtained from the livers of non-human primates infected with hepatitis A (infectious hepatitis) virus has been found to be usable in fast, simple assays for hepatitis A antibody and thus usable in diagnosis of hepatitis A disease in humans, and for the preparation of hepatitis A vaccine.
Claims22
A composition consisting essentially of a physiological saline solution buffered at from about pH 6.0 to about pH 7.8 containing hepatitis A antigen having a buoyant density in CsCl of from about 1.32 g/cm.sup.3 to about 1.36 g/cm.sup.3 in concentration effective to give a measurable reaction with hepatitis A antibody in an immune adherence serological assay.
A vaccine to prevent hepatitis A disease consisting essentially of a physiological saline solution buffered at from about pH 6.0 to about pH 7.8 containing inactivated or attenuated hepatitis A antigen in quantity effective to induce immunity to hepatitis A virus, the antigen having a buoyant density in CsCl of from about 1.32 g/cm.sup.3 to about 1.36 g/cm.sup.3.
A vaccine against hepatitis A consisting essentially of inactivated or attenuated hepatitis A antigen of a particle size of 27 m.mu. and a buoyant density in CsCl of from about 1.32 g/cm.sup.3 to about 1.36 g/cm.sup.3 and being in an amount sufficient to induce formation of antibodies, and a physiologically acceptable medium.
A composition consisting essentially of hepatitis A antigen of a particle size of 27 m.mu. and a buoyant density in CsCl of from about 1.32 g/cm.sup.3 to about 1.36 g/cm.sup.3 and a physiologically acceptable medium.
A composition consisting essentially of hepatitis A antigen and a physiologically acceptable medium, the antigen having a buoyant density in CsCl of from about 1.32 g/cm.sup.3 to about 1.36 g/cm.sup.3.
Dependencies are inferred from the claim text.